David Lebowitz Analyst PerformanceAnalyst at BMO Capital MarketsDavid Lebowitz is a stock analyst at BMO Capital Markets in the healthcare sector, covering 19 publicly traded companies. Over the past year, David Lebowitz has issued 23 stock ratings, including strong buy, buy, and hold recommendations. While full access to David Lebowitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebowitz's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings42 Last 1 YearsBuy Recommendations73.81% 31 Buy RatingsCompanies Covered19 Unique Companies Ratings Distribution42RatingsDistribution of strong buy, buy, hold, and sell ratings by David Lebowitz.RatingPercentageCount Strong Buy9.5%4 ratings Buy64.3%27 ratings Hold23.8%10 ratings Sell2.4%1 ratingsOut of 42 total stock ratings issued by David Lebowitz at BMO Capital Markets, the majority (64.3%) have been Buy recommendations, followed by 23.8% Hold, 9.5% Strong Buy, and 2.4% Sell.Best & Worst CallsBest Call0000.0%COGTJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%EXELMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ94.7% of companies on NASDAQ18 companiesNYSEAMERICAN5.3% of companies on NYSEAMERICAN1 companyDavid Lebowitz, an analyst at BMO Capital Markets, currently covers 19 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare19 companies100.0%David Lebowitz of BMO Capital Markets specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY18 companies94.7%HEALTHCARE TECHNOLOGY1 company5.3% David Lebowitz's Ratings History at BMO Capital Markets Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIONSIonis Pharmaceuticals8/19/2026Initiated Coverage$59.62$60.00Market Perform$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/19/2026Initiated Coverage$66.99$98.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals8/19/2026Initiated Coverage$228.61$318.00Outperform$0.0000.00% ROIEXELExelixis8/18/2026Initiated Coverage$53.12$54.00Market Perform$0.0000.00% ROIPRMEPrime Medicine8/18/2026Initiated Coverage$3.05$9.00Outperform$0.0000.00% ROICATXPerspective Therapeutics8/18/2026Set Price Target$3.21$11.00Outperform$0.0000.00% ROIAKTSAktis Oncology8/18/2026Initiated Coverage$25.00$37.00Outperform$0.0000.00% ROIASNDAscendis Pharma A/S8/18/2026Initiated Coverage$248.85$319.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics8/18/2026Initiated Coverage$24.92$35.00Outperform$0.0000.00% ROIAKTSAktis Oncology8/18/2026Initiated Coverage$25.02Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ALNYAlnylam Pharmaceuticals8/18/2026Upgrade$242.61Strong-Buy$0.0000.00% ROIASNDAscendis Pharma A/S8/18/2026Initiated Coverage$259.62Outperform$0.0000.00% ROIBCAXBicara Therapeutics8/18/2026Upgrade$25.86Strong-Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/18/2026Upgrade$69.33Strong-Buy$0.0000.00% ROICATXPerspective Therapeutics8/18/2026Upgrade$3.48Strong-Buy$0.0000.00% ROIEXELExelixis8/18/2026Initiated Coverage$54.39Hold$0.0000.00% ROIIONSIonis Pharmaceuticals8/18/2026Upgrade$60.80Hold$0.0000.00% ROIPRMEPrime Medicine8/18/2026Initiated Coverage$3.54Outperform$0.0000.00% ROICYTKCytokinetics12/22/2025Reiterated Rating$62.72Market Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals9/3/2025Boost Price Target$60.15$84.00Buy$0.0000.00% ROICYTKCytokinetics9/2/2025Boost Price Target$48.12$84.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals8/22/2025Boost Price Target$42.29$69.00Buy$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$21.36$48.00Buy$00.0000.00% ROISDGRSchrodinger8/15/2025Downgrade$19.45$20.00Neutral$00.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Reiterated Rating$191.49$290.00Buy$000.0000.00% ROICYTKCytokinetics8/8/2025Lower Price Target$34.11$77.00Buy$00.0000.00% ROIINCYIncyte7/30/2025Boost Price Target$78.05$103.00Buy$000.0000.00% ROIVKTXViking Therapeutics7/24/2025Boost Price Target$33.29$38.00Neutral$00.0000.00% ROICOGTCogent Biosciences7/18/2025Boost Price Target$12.46$22.00Buy$00.0000.00% ROIBBIOBridgeBio Pharma7/11/2025Boost Price Target$46.34$67.00Buy$00.0000.00% ROIASNDAscendis Pharma A/S7/11/2025Boost Price Target$175.67$243.00Buy$000.0000.00% ROIEXELExelixis5/15/2025Boost Price Target$47.21$56.00Buy$00.0000.00% ROINTLAIntellia Therapeutics5/9/2025Lower Price Target$8.38$10.00Neutral$00.0000.00% ROINTLAIntellia Therapeutics2/28/2025Boost Price Target$9.88$14.00Neutral$00.0000.00% ROIBBIOBridgeBio Pharma2/21/2025Boost Price Target$36.88$49.00Buy$00.0000.00% ROIIONSIonis Pharmaceuticals2/20/2025Lower Price Target$32.57$64.00Buy$00.0000.00% ROIPTCTPTC Therapeutics2/12/2025Boost Price Target$48.63$45.00Sell$00.0000.00% ROIEXELExelixis2/12/2025Boost Price Target$33.18$45.00Buy$00.0000.00% ROIINCYIncyte2/11/2025Lower Price Target$68.30$88.00Buy$000.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79$4.00Neutral$0.0000.00% ROIThese 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI (Ad)Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture after OpenAI, one some say could be 500 times bigger than ChatGPT. Test staff are said to be bound by law to keep details secret, and three lesser-known stocks may be tied to this next chapter in AI.Click here to see the stocks linked to Altman's next big moveCYTKCytokinetics2/7/2025Initiated Coverage$46.17$86.00Buy$00.0000.00% ROIVKTXViking Therapeutics2/7/2025Initiated Coverage$31.46$38.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
